Your browser doesn't support javascript.
loading
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
Lee, Brian P; Dodge, Jennifer L; Terrault, Norah A.
Afiliação
  • Lee BP; Division of Gastroenterology and Liver Diseases, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
  • Dodge JL; Institute for Addiction Science, University of Southern California, Los Angeles, California, USA.
  • Terrault NA; Division of Gastroenterology and Liver Diseases, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
Hepatology ; 79(3): 666-673, 2024 Mar 01.
Article em En | MEDLINE | ID: mdl-37732946
BACKGROUND AND AIMS: The multisociety consensus nomenclature has renamed NAFLD to steatotic liver disease (SLD) with various subclassifications. There is a paucity of data regarding how the new nomenclature modifies our understanding of disease prevalence and patient phenotypes. APPROACH AND RESULTS: Using the National Health and Nutrition Examination Survey from January 2017 to March 2020, we included all participants aged 18 years or above with complete vibration-controlled transient elastography measures. SLD and its subclassifications [metabolic dysfunction-associated SLD (MASLD), MASLD + increased alcohol intake (MetALD), alcohol-associated liver disease (ALD), etiology-specific/cryptogenic] were defined according to consensus nomenclature. National SLD prevalence and subclassifications were estimated, and among key subgroups [age, sex, race/ethnicity, advanced liver fibrosis (liver stiffness measurement [LSM] ≥11.7 kPa)]. Among 7367 participants, 2549 had SLD (mean age 51 y, 57.7% male, 63.2% non-Hispanic White). The estimated prevalence of SLD was 34.2% (95% CI 31.9%-36.5%): MASLD 31.3% (29.2%-33.4%), MetALD 2% (1.6%-2.9%), ALD 0.7% (0.5-0.9%), etiology-specific/cryptogenic 0.03% (0.01%-0.08%). In exploratory analyses, participants classified as non-SLD with (vs. without) advanced fibrosis had a higher mean number of metabolic risk factors [2.7 (2.3-3.1) vs. 2.0 (1.9-2.0)] and a higher proportion with average alcohol use ≥20 g/d (women)/≥30 g/d (men) [20.9% (6.2%-51.3%) vs. 7.2% (6.1%-8.4%)]. In another exploratory analysis, increasing quantities of alcohol use remaining below the threshold for MASLD + increased alcohol intake were associated with advanced liver fibrosis in men, but not women. There was 99% overlap in cases of NAFLD and MASLD. CONCLUSIONS: Our findings highlight the utility of the new consensus nomenclature to address deficiencies present with the old nomenclature, and identify areas that require research to further refine classifications of SLD.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica / Hepatopatias Alcoólicas Tipo de estudo: Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Hepatology Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica / Hepatopatias Alcoólicas Tipo de estudo: Prevalence_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Hepatology Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos